Effect of antimicrobial administration on fecal microbiota of critically ill dogs: dynamics of antimicrobial resistance over time.
Antimicrobial resistance genes
Enterococcus
Escherichia coli
Microbiota
Sepsis
Veterinary
Journal
Animal microbiome
ISSN: 2524-4671
Titre abrégé: Anim Microbiome
Pays: England
ID NLM: 101759457
Informations de publication
Date de publication:
04 Jun 2022
04 Jun 2022
Historique:
received:
22
10
2021
accepted:
01
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Multidrug resistance in companion animals poses significant risks to animal and human health. Prolonged antimicrobial drug (AMD) treatment in animals is a potential source of selection pressure for antimicrobial resistance (AMR) including in the gastrointestinal microbiota. We performed a prospective study of dogs treated for septic peritonitis, pyometra, or bacterial pneumonia and collected repeated fecal samples over 60 days. Bacterial cultures and direct molecular analyses of fecal samples were performed including targeted resistance gene profiling. Resistant Escherichia coli increased after 1 week of treatment (D1:21.4% vs. D7:67.9% P < 0.001) and returned to baseline proportions by D60 (D7:67.9% vs D60:42.9%, P = 0.04). Dogs with septic peritonitis were hospitalized significantly longer than those with pneumonia or pyometra. Based on genetic analysis, Simpson's diversity index significantly decreased after 1 week of treatment (D1 to D7, P = 0.008), followed by a gradual increase to day 60 (D1 and D60, P = 0.4). Detection of CTX-M was associated with phenotypic resistance to third-generation cephalosporins in E. coli (OR 12.1, 3.3-68.0, P < 0.001). Lincosamide and macrolide-resistance genes were more frequently recovered on days 14 and 28 compared to day 1 (P = 0.002 and P = 0.004 respectively). AMR was associated with prescribed drugs but also developed against AMDs not administered during the study. Companion animals may be reservoirs of zoonotic multidrug resistant pathogens, suggesting that veterinary AMD stewardship and surveillance efforts should be prioritized.
Sections du résumé
BACKGROUND
BACKGROUND
Multidrug resistance in companion animals poses significant risks to animal and human health. Prolonged antimicrobial drug (AMD) treatment in animals is a potential source of selection pressure for antimicrobial resistance (AMR) including in the gastrointestinal microbiota. We performed a prospective study of dogs treated for septic peritonitis, pyometra, or bacterial pneumonia and collected repeated fecal samples over 60 days. Bacterial cultures and direct molecular analyses of fecal samples were performed including targeted resistance gene profiling.
RESULTS
RESULTS
Resistant Escherichia coli increased after 1 week of treatment (D1:21.4% vs. D7:67.9% P < 0.001) and returned to baseline proportions by D60 (D7:67.9% vs D60:42.9%, P = 0.04). Dogs with septic peritonitis were hospitalized significantly longer than those with pneumonia or pyometra. Based on genetic analysis, Simpson's diversity index significantly decreased after 1 week of treatment (D1 to D7, P = 0.008), followed by a gradual increase to day 60 (D1 and D60, P = 0.4). Detection of CTX-M was associated with phenotypic resistance to third-generation cephalosporins in E. coli (OR 12.1, 3.3-68.0, P < 0.001). Lincosamide and macrolide-resistance genes were more frequently recovered on days 14 and 28 compared to day 1 (P = 0.002 and P = 0.004 respectively).
CONCLUSION
CONCLUSIONS
AMR was associated with prescribed drugs but also developed against AMDs not administered during the study. Companion animals may be reservoirs of zoonotic multidrug resistant pathogens, suggesting that veterinary AMD stewardship and surveillance efforts should be prioritized.
Identifiants
pubmed: 35659110
doi: 10.1186/s42523-022-00178-9
pii: 10.1186/s42523-022-00178-9
pmc: PMC9167539
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Subventions
Organisme : FDA HHS
ID : U18 FD006379
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2014 Sep 17;9(9):e107909
pubmed: 25229475
PLoS One. 2012;7(6):e39333
pubmed: 22720094
Nat Microbiol. 2016 Oct 03;1:16177
pubmed: 27694806
Anaerobe. 2015 Feb;31:72-7
pubmed: 25445201
Epidemiol Infect. 2011 Oct;139(10):1511-21
pubmed: 21156096
J Antimicrob Chemother. 2018 Feb 1;73(2):377-384
pubmed: 29136156
J Vet Med Sci. 2017 Nov 17;79(11):1840-1847
pubmed: 28993566
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
FEMS Microbiol Ecol. 2008 Dec;66(3):567-78
pubmed: 18557939
PLoS One. 2018 Mar 16;13(3):e0192198
pubmed: 29547647
PLoS One. 2011;6(7):e22451
pubmed: 21811613
Zoonoses Public Health. 2013 Mar;60(2):160-7
pubmed: 22646722
Vet J. 2013 Oct;198(1):259-66
pubmed: 23702279
Appl Environ Microbiol. 2009 Apr;75(8):2360-5
pubmed: 19233953
J Am Vet Med Assoc. 2006 Sep 1;229(5):694-9
pubmed: 16948576
J Vet Intern Med. 2017 Mar;31(2):279-294
pubmed: 28185306
J Am Vet Med Assoc. 2007 May 15;230(10):1493-7
pubmed: 17504040
Mol Microbiol. 2007 Jan;63(2):530-44
pubmed: 17163979
Microorganisms. 2020 Feb 17;8(2):
pubmed: 32079318
Am J Respir Crit Care Med. 2015 Sep 1;192(5):581-8
pubmed: 26016947
Emerg Infect Dis. 2020 Feb;26(2):381-383
pubmed: 31961309
Emerg Microbes Infect. 2018 Nov 30;7(1):197
pubmed: 30498207
J Antimicrob Chemother. 2018 Dec 1;73(12):3305-3316
pubmed: 30215725
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
J Vet Intern Med. 2020 Sep;34(5):1853-1866
pubmed: 32856349
Br J Nutr. 2015 Jan;113 Suppl:S6-17
pubmed: 25414978
J Vet Intern Med. 2010 Sep-Oct;24(5):1034-47
pubmed: 20629945
N Engl J Med. 2015 May 21;372(21):1996-2005
pubmed: 25992746
Vet Med Int. 2013;2013:658373
pubmed: 23738233
J Vet Emerg Crit Care (San Antonio). 2015 Jan-Feb;25(1):152-9
pubmed: 25545023
Top Companion Anim Med. 2018 Dec;33(4):126-135
pubmed: 30502863
PLoS Biol. 2008 Nov 18;6(11):e280
pubmed: 19018661
Microb Ecol. 2002 Aug;44(2):186-97
pubmed: 12087428
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
New Microbiol. 2015 Jul;38(3):369-78
pubmed: 26147147
Front Vet Sci. 2020 Jan 14;6:498
pubmed: 31993446
Clin Infect Dis. 2012 Oct;55(7):905-14
pubmed: 22718773
J Vet Med Sci. 2014 Oct;76(10):1399-402
pubmed: 24976587
J Small Anim Pract. 2011 Oct;52(10):515-21
pubmed: 21824147
Crit Care Clin. 2016 Apr;32(2):203-12
pubmed: 27016162
PLoS One. 2010 Mar 22;5(3):e9768
pubmed: 20339542
Anaerobe. 2017 Jun;45:50-58
pubmed: 28223257
Can J Microbiol. 2012 Nov;58(11):1288-94
pubmed: 23145826
J Med Microbiol. 2004 May;53(Pt 5):439-443
pubmed: 15096555
J Small Anim Pract. 2013 Dec;54(12):625-9
pubmed: 24283417
Front Microbiol. 2016 Jan 12;6:1543
pubmed: 26793178
FEMS Microbiol Ecol. 2010 Feb;71(2):313-26
pubmed: 20002181
J Vet Intern Med. 2020 May;34(3):1166-1176
pubmed: 32324947
Vet J. 2017 Jun;224:18-24
pubmed: 28697871
Am J Vet Res. 2007 Dec;68(12):1281-6
pubmed: 18052731
Nucleic Acids Res. 2014 Jan;42(Database issue):D633-42
pubmed: 24288368
J Vet Med Sci. 2017 Jun 16;79(6):1024-1030
pubmed: 28450661
Vet Rec. 2005 Aug 13;157(7):193-6
pubmed: 16100369
J Vet Emerg Crit Care (San Antonio). 2014 Mar-Apr;24(2):194-200
pubmed: 24382329
BMC Microbiol. 2014 Jul 12;14:187
pubmed: 25014994
Front Vet Sci. 2019 Jun 27;6:208
pubmed: 31316998
Nat Rev Immunol. 2013 Nov;13(11):790-801
pubmed: 24096337
Clin Infect Dis. 2015 May 15;60 Suppl 2:S77-84
pubmed: 25922405
Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011
pubmed: 18947320
Vet Microbiol. 2008 Nov 25;132(1-2):190-6
pubmed: 18524501
J Antimicrob Chemother. 2019 Mar 1;74(3):782-786
pubmed: 30418539
Microb Drug Resist. 2016 Oct;22(7):609-615
pubmed: 27314838
Emerg Infect Dis. 1998 Apr-Jun;4(2):239-49
pubmed: 9621194
J Appl Microbiol. 2010 Jun;108(6):2171-9
pubmed: 19968729
BMC Microbiol. 2009 Oct 02;9:210
pubmed: 19799792